header logo image


Page 903«..1020..902903904905..910920..»

Houston Lake Animal Hospital, Warner Robins, GA

March 4th, 2019 7:43 pm

Houston Lake Animal Hospital, Warner Robins, GA

We invite you to contact us today to discuss your pets care. Call us at 478-971-4700.

Exercise has many advantages for our pets. Click here to learn about some of them!

Click here for helpful information about preventing parasites in your pet.

Houston Lake Animal Hospital is proud to serve Warner Robins, GA and the surrounding areas. We are dedicated to providing the highest level of veterinary medicine along with friendly, compassionate service.

View details

We welcome all new clients to our veterinary facility. We invite you to contact us today. If you have any questions or concerns, please don't hesitate to call us at 478-971-4700.

View details

We value our patients and clients, and we appreciate the role we get to play in your pet's health care. Check this page for different specials that will help you save on services and products.

View details

Contrast

black white green blue red orange yellow navi

Here is the original post:
Houston Lake Animal Hospital, Warner Robins, GA

Read More...

Arthritis | Crohns & Colitis Foundation

March 3rd, 2019 10:41 am

Arthritis, or inflammation of the joints, is the most common extraintestinal complication of IBD. It may affect as many as 25% of people with Crohns disease or ulcerative colitis. Although arthritis is typically associated with advancing age, in IBD it often strikes the youngest patients. In addition to joint pain, arthritis also causes swelling of the joints and a reduction in flexibility.

In IBD, arthritis may appear in three different forms. These are:

Peripheral arthritis usually affects the large joints of the arms and legs, including the elbows, wrists, knees, and ankles. The discomfort may be migratory, moving from one joint to another. If left untreated, the pain may last from a few days to several weeks. Peripheral arthritis tends to be more common among people who have ulcerative colitis or Crohns disease of the colon. The level of inflammation in the joints generally mirrors the extent of inflammation in the colon. Although no specific test can make a definitive diagnosis, various diagnostic methodsincluding analysis of joint fluid, blood tests, and X-raysare used to rule out other causes of joint pain. Fortunately, IBD-related peripheral arthritis usually does not cause any lasting damage.

Also known as spondylitis or spondyloarthropathy, axial arthritis produces pain and stiffness in the lower spine and sacroiliac joints (at the bottom of the back). Interestingly, and especially in young people, these symptoms may come on months or even years before the symptoms of IBD appear. Unlike peripheral arthritis, axial arthritis may cause permanent damage if the bones of the vertebral column fuse togetherthereby creating decreased range of motion in the back. In some cases, a restriction in rib motion may make it difficult for people to take deep breaths. Active spondylitis generally subsides by age 40. Therapy for people with axial arthritis is geared toward improving range of motion in the back. Stretching exercises are recommended, as is the application of moist heat to the back.

A more severe form of spinal arthritis, ankylosing spondylitis (AS) is a rare complication, affecting between 2% and 3% of people with IBD. It is seen more often in Crohns disease than in ulcerative colitis. In addition to causing arthritis of the spine and sacroiliac joints, ankylosing spondylitis can cause inflammation of the eyes, lungs, and heart valves. The cause of AS is not known, but most affected individuals share a common genetic marker. In some cases, the disease occurs in genetically predisposed people after exposure to bowel or urinary tract infections. Occasionally, AS foretells the development of IBD. AS typically strikes people under the age of 30, mainly adolescents and young adult males, appearing first as a dramatic loss of flexibility in the lower spine. Rehabilitation therapy is essential to help maintain joint flexibility. But even with optimal therapy, some people will develop a stiff or ankylosed spine. Symptoms of AS may continue to worsen even after surgical removal of the colon.

It is not always easy to determine whether the arthritis is linked to the intestinal condition. In general, the arthritis that complicates IBD is not as severe as rheumatoid arthritis. The joints do not ordinarily undergo destructive changes, and joint involvement is not symmetric (affecting the same joints on both sides of the body). Except for ankylosing spondylitis, arthritis associated with IBD usually improves as intestinal symptoms improve.

In the general population, people with peripheral arthritis may use nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce pain and swelling of the joints. However, as a rule, these medicationswhich include aspirin and ibuprofen are not an option for everyone with IBD because they can prompt a disease flare by irritating the intestinal lining and intensifying the inflammation. (It should be noted, though, that some people with IBD can tolerate NSAIDs and find these medications helpful in relieving symptoms of arthritis.) Corticosteroids also may be used to treat the arthritis symptoms as well as IBD.

In most cases, doctors manage the symptoms of peripheral arthritis by controlling the inflammation within the colon. Once that has subsided after a course of a medication such as prednisone or sulfasalazine, joint pain generally disappears. Similarly, the newer biologic agents such as infliximab (Remicade) have also been shown to be effective in reducing joint inflammation and swelling. Infliximab has even shown good results as a treatment for ankylosing spondylitis. Only axial arthritis seems not to improve as the intestinal inflammation resolves. Unlike peripheral arthritis, there is no correlation between treatment of the underlying IBD and improvement in axial arthritis symptoms.

In addition to medication, doctors may recommend resting the affected joint as well as the occasional use of moist heat. Range of motion exercises, as demonstrated by a physical therapist, may also be helpful.

The Crohns & Colitis Foundation of America provides information for educational purposes only. We encourage you to review this educational material with your health care professional. The Foundation does not provide medical or other health care opinions or services. The inclusion of another organizations resources or referral to another organization does not represent an endorsement of a particular individual, group, company or product.

For further information, call Crohn's & Colitis Foundation's IBD Help Center: 888.MY.GUT.PAIN (888.694.8872).

The Crohn's & Colitis Foundation provides information for educational purposes only. We encourage you to review this educational material with your health care professional. The Foundation does not provide medical or other health care opinions or services. The inclusion of another organization's resources or referral to another organization does not represent an endorsement of a particular individual, group, company or product.

Questions or Want to Talk?

Visit link:
Arthritis | Crohns & Colitis Foundation

Read More...

Stem Cell Vet UK Treat Arthritis in Dogs & Cats

February 28th, 2019 12:46 pm

The procedure is carried out in one day as an outpatient, and patients generally do not need an overnight stay with us.

We need some blood tests for anesthetic safety. Once we are happy with these, we administer a short general anesthetic. Typically this lasts 30 to 90 minutes.

We need to take x-rays of the affected areas and also a chest x-ray. Where recent x-rays are available from your own vet, we will not need to repeat these.

We then harvest approximately 40 grams of fat from a site behind the shoulder or just inside the tummy. At this time we may inject Platelet Rich Plasma (PRP) into the affected joints. This reduces inflammation and pain in the joint and prepares it to receive stem cells, should they be required. Your pet is then woken from the anesthetic. There may be a few stitches that need to come out in 10 days.

The fat is processed in our lab to isolate, concentrate and activate stem cells and this takes 10-14 days. Once we have the healthy stem cells, we organise a second appointment for a sedative to allow us to inject the cells directly into the affected joints.

Well then book you follow up consultations at 30, 60 and 90 days.

We ask you to send us follow up videos and updates on a weekly basis so we can keep a close eye on progress.Where repeat visits are difficult because of travel distances, we can arrange telephone consultations.

Read the original post:
Stem Cell Vet UK Treat Arthritis in Dogs & Cats

Read More...

Careers in Veterinary Medicine – aavmc.org

February 28th, 2019 12:44 pm

You can view a list of potential veterinary career paths here.

Whether they're pets, livestock or working animals, animals matter to individuals and society. Every community needs veterinary professionals to provide animal health care, but veterinarians also do many other kinds of jobs. They make sure the nation's food supply is safe. They work to control the spread of diseases. They conduct research that helps both animals and humans. Veterinarians are at the forefront of protecting the public's health and welfare.

Besides medical skills, veterinarians often take a holistic approach to human well-being and animal welfare that, combined with communications and problem-solving skills, makes veterinarians uniquely qualified to fulfill a variety of roles. Many veterinarians, of course, provide care for companion animals through private medical practices, but veterinarians are also involved in promoting the health and welfare of farm animals, exotic animals, working animals (like those in the equine industry), and those that need a healthy environment in which to thrive, whether that environment is a rain forest, a desert or even the ocean.

Outside of companion animal practice, the largest employer of veterinarians in the United States is the U.S. Department of Agriculture's Food Safety and Inspection Service, but veterinarians are found throughout government in roles where they contribute to public health, the environment, and even homeland security, as well as working in research and public policy.

Many veterinarians are engaged in work at the intersection of both human and animal health. For example, veterinarians play an important role in food safety, where epidemiological research is crucial to forecasting the threat of food-borne diseases and outbreaks. They work to keep cattle and other food animals healthy by developing and testing various farm control methods that help to detect, limit, and prevent the spread of food that might be contaminated by salmonella, E coli or other pathogens. And theyre often on the front lines of surveillance where their extensive medical training can help them to detect and treat the outbreak of diseases that have the potential to make the jump from animals to humans.

Unmet needs for veterinary expertise exist in some sectors of veterinary medicine, such as public health, biomedical research, and food safety. To help address the lack of veterinarians in biomedical research, the AAVMC is a co-sponsor of the Merial Veterinary Scholars Program. The program's mission is to expose veterinary medical students in their first or second year of veterinary school to biomedical research and career opportunities in research. The program culminates in the Merial NIH National Veterinary Scholars Symposium, where veterinary students participating in the program gather from all over the United States and Canada to present their research findings and share experiences from their various programs.

Learn more about how to embark on a path that will lead to a veterinary medical career on our Students, Applicants and Advisors portal.

Read more here:
Careers in Veterinary Medicine - aavmc.org

Read More...

what are the negative aspects to stem cell therapy …

February 27th, 2019 9:46 pm

It's not so much the acutal medical risks, but the ehtical and moral implications of conducting research in the field.

The following is an excerpt from a research paper I recently wrote concerning stem cell research:

Embryonic stem cell research raises immense ethical and religious concern: The issue of research involving stem cells derived from human embryos is increasingly the subject of a national debate and dinner table discussions. The issue is confronted every day in laboratories as scientists ponder the ethical ramifications of their work. It is agonized over by parents and many couples as they try to have children or to save children already born. The issue is debated within the church, with people of different faiths- even many of the same faith- coming to different conclusions. Many people are finding the more they know about stem cell research, the less certain they are about the right ethical and moral conclusions. (Bush Embryonic Stem Cell Decision 1) Quite often, the status of an embryo is debated among scientists, politicians, theologians, philosophers, and even everyday people. There are many ideas circulating the globe as some vie to protect the embryo and others hope to use it to benefit society. Those that oppose stem cell research claim that the methods scientists use are not morally justifiable. Human embryos, in their minds, are not mere biological tissues or clusters of cells; they are the tiniest of human beings (Espejo 49). According to the Human Embryo Research Panel and the National Bioethics Commission, the embryo should be considered a living organism from its earliest stages (Espejo 46-50). People therefore claim that scientists are alienating the rights of living human beings by performing experiments on embryos: The painful lessons of the past should have taught us that human beings must not be conscripted for research without their permission- no matter what the alleged justification- especially when that research means the forfeiture of their health or lives. Even if an individuals death is believed to be otherwise imminent, we still do not have a license to engage in lethal experimentation- just as we may not experiment on death row prisoners or harvest their organs without their consent. (Espejo 49) The widespread Christian view that life begins at the moment of conception has caused many to believe that the destruction of the human embryo is murder (Espejo 4). People also believe that is irrelevant whether the embryos are capable of implanting in a uterus and developing, as they are embryos nonetheless (Morris 2). As Morris questions, are we willing to recognize life, even if its living in a Petri dish? (2). Those that sympathize with these concerns feel that research requiring the destruction of a human embryo should be banned. Others argue that since IVF procedures often generate more embryos than needed, the excess embryos should be used for potentially life-saving research rather than being discarded (Espejo 36-37). Also, they claim embryos do not have the same rights as adult humans. The suggestion that a mass of 50-100 cells with no heart and no brain is entitled to the same protections is unprecedented and not embodied in American law (Espejo 38). With this in mind, it seems that embryonic stem cell research should not be undermined by the aforementioned arguments. There are additional concerns however. The use of SCNT is often criticized by those opposed to cloning, as a majority of people view cloning as morally wrong. SCNT has been used in reproductive cloning, such as the cloning of Dolly the sheep. In the publics mind, the distinction between this form of cloning and therapeutic cloning, which involves SCNT used for medical purposes, has blurred. The two should not be confused however, as they are completely separate procedures. Outlawing the use of SCNT would prevent the development of very promising techniques for curing disease, such as the one mentioned earlier (Scott 49-56). Finally, there are claims that the science will not live up to the hope that has been generated. Opponents of stem cell research are quick to point out that stem cell technologies are still at a developmental stage and it is virtually impossible to predict the eventual outcomes of innovation in the field (Stem Cell Controversy 2). Some have even claimed that researchers have falsely raised peoples expectations in an attempt to secure funding and support (Stem Cell Controversy 2). Such statements should not be regarded as wholly true, but with ideas such as these spreading around the globe, it is no wonder why the topic has become so controversial.

Granted, it's somewhat lengthy, but there is alot of information in there. If you want me to send you the whole paper sometime, just let me know. But please, if you're using this for your own schoolwork, avoid plagarism.

Hope this helps!

See original here:
what are the negative aspects to stem cell therapy ...

Read More...

Stem Cell Therapy for Autism in Turkey – health-tourism.com

February 27th, 2019 9:44 pm

This information is intended for general information only and should not be considered as medical advice on the part of Health-Tourism.com. Any decision on medical treatments, after-care or recovery should be done solely upon proper consultation and advice of a qualified physician.

What is autism?

Autism is an array of disorders which are characterized by visible abnormalities in social interactions and communication. The common medical findings associated in children with the disorder are a chronic immunologically mediated inflammatory condition in the gut and reduced oxygenation in specific areas of the brain.

Current research aims at attempting to reverse the abnormalities through administration of anti-inflammatory agents, antibiotic and hyperbaric oxygen. However, none of these approaches address the underlying causes of the intestinal inflammation or oxygen deprivation.

It is thought that mesenchymal stem cells may help reverse inflammatory conditions and regulate the immune system. The umbilical cord-derived mesenchymal stem cells are administered intravenously by a licensed doctor.

Adult stem cells used to treat autism are harvested from human umbilical cord tissue also called allogenic mesenchymal. The human umbilical cords are donated by mothers after healthy and normal births. They are thoroughly screened and tested for bacteria and viruses.

They are idea for the treatment of autism because they allow for the administering of uniform doses and do not necessitate any stem cell harvesting from the patient, which can be quite concerning for the parents and terrifying for the autistic child. Because the stem cells are collected immediately after birth the umbilical cord-derived cells are much more effective than their counterparts such as bone marrow derived cells.

In addition the umbilical cord derived mesenchymal cells are not rejected by the patient because they do not recognize them as foreign. This is due to the fact that the HUCT stem cells are less mature than other cells. HUCT stem cells also differentiate/proliferate better that older cells and are therefore considered to be more potent.

A typical autism treatment protocol takes about 5 days and involves blood tests and physical examination. Intravenous infusions of the mesenchymal cells are then administered.

The cells are not rejected because the HUCT mesenchymal stem cells are immune system privileged and Human Leukocyte (HLA) matching is not required.

Screening and testing of the best stem cells can be conducted to ensure that the best immune modulating capacity, anti-inflammatory and regeneration stimulation cells are selected.

Administering of uniform dosages with high cell counts can be done with the allogenic stem cells.

The umbilical cord tissue provides a supply of mesenchymal stem cells in abundance.

There is no need to harvest stem cells from the patient under anesthesia which can be very unpleasant t the child.

Umbilical cord-derived mesenchymal stem cells are thought by researchers to be more robust than mesenchymal stem cells harvested from other sources.

Proper follow up after the procedure is necessary to ensure that the patient is progressing well.

See original here:
Stem Cell Therapy for Autism in Turkey - health-tourism.com

Read More...

Integrative Medicine – 9780323358682 | US Elsevier Health …

February 26th, 2019 10:57 pm

Part I INTEGRATIVE MEDICINE

1. The Philosophy of Integrative Medicine

2. Creating Optimal Healing Environments

3. The Healing Encounter

4. The Whole Health Process

Part II INTEGRATIVE APPROACH TO DISEASE

Section 1. Affective Disorders

5. Depression

6. Anxiety

7. Attention Deficit Disorder

8. Autism Spectrum Disorder

9. Insomnia

10. Posttraumatic Stress Disorder (PTSD)

Section 2. Neurology

11. Alzheimer's Disease

12. Headache

13. Peripheral Neuropathy

14. Multiple Sclerosis

15. Parkinson's Disease

Section 3. Infectious Disease

16. Otitis Media

17. Chronic Sinusitis

18. Viral Upper Respiratory Infection

19. HIV/AIDS

20. Herpes Simplex Virus

21. Chronic Hepatitis

22. Urinary Tract Infection (UTI)

23. Lyme Disease

Section 4. Cardiovascular Disease

24. Hypertension

25. Heart Failure

26. Coronary Artery Disease

27. Dyslipidemia

28. Cardiac Arrhythmia

Section 5. Allergy/Intolerance

29. Asthma

30. The Allergic Patient

31. Food Allergy and Intolerance

Section 6. Metabolic/Endocrine Disorders

32. Insulin Resistance and the Metabolic Syndrome

33. Diabetes Mellitus

34. Hypothyroidism

35. Polycystic Ovarian Syndrome

36. Osteoporosis

37. Obesity

38. MTHFR, Homocysteine and Nutrient Needs

39. Adrenal Fatigue

Section 7. Nephrology

40. Chronic Kidney Disease

Section 8. Gastrointestinal Disorders

41. Irritable Bowel Syndrome

42. Gastroesophageal Reflux Disease

43. Peptic Ulcer Disease

44. Cholelithiasis

45. Recurring Abdominal Pain in Pediatrics

46. Constipation

Section 9. Autoimmune Disorders

47. Fibromyalgia

48. Chronic Fatigue Syndrome

49. Rheumatoid Arthritis

50. Inflammatory Bowel Disease

Section 10. Obstetrics/Gynecology

51. Preconception Counseling and Fertility

52. Labor Pain Management

53. Postdates Pregnancy

54. Nausea and Vomiting in Pregnancy

55. Menopause

56. Premenstrual Syndrome

57. Dysmenorrhea

58. Leiomyomata

59. Vaginal Dryness

Section 11. Urology

60. Benign Prostatic Hyperplasia

61. Urolithiasis

62. Chronic Prostatitis

63. Erectile Dysfunction

64. Testosterone Deficiency

Section 12. Musculoskeletal

65. Osteoarthritis

66. Myofascial Pain Syndrome

67. Chronic Low Back Pain

68. Neck Pain

69. Gout

70. Carpal Tunnel Syndrome

71. Epicondylosis

Section 13. Dermatology

72. Atopic Dermatitis

73. Psoriasis

74. Urticaria

75. Aphthous Stomatitis

76. Seborrheic Dermatitis

77. Acne/Rosacea

Section 14. Cancer

78. Breast Cancer

79. Lung Cancer

80. Prostate Cancer

81. Colon Cancer

82. Palliative and End of Life Care

Section 15. Substance Abuse

83. Alcoholism and Substance Abuse

The rest is here:
Integrative Medicine - 9780323358682 | US Elsevier Health ...

Read More...

Center for Integrative Medicine Team – Detroit, MI

February 26th, 2019 10:57 pm

Kathryn Glad

Licensed Massage Therapist (LMT)View Profile Video

Kathryn is a board-certified, licensed massage therapist who is dedicated to using massage to improve the lives of others. She has experience in both clinical and spa settings and offers a variety of massage styles designed to fit each patients unique needs. Her specialties include deep tissue, prenatal, oncology, aromatherapy, Thai, Swedish and reflexology.

Kathryn is passionate about the benefits of massage and feels its effects can be life changing. She enjoys working with patients to assess their individual health needs and determine how massage can help. As massage can be a great complement to traditional medical care, Kathryn often partners with other health care providers to help patients reach their treatment goals. She has a personal interest in using massage to relieve the effects of cancer treatment.

Kathryn is licensed by the state of Michigan and board certified by the National Certification Board for Therapeutic Massage and Bodywork. She received her training from Irenes Myomassology Institute one of Michigans oldest and highest regarded schools of massage therapy. She has an additional certification in oncology massage through Beaumont Hospital.

Licensed Massage Therapist (LMT)

Anita M. Gosselin is a board-certified, licensed massage therapist at the Henry Ford Center for Integrative Medicine. She is dedicated to helping people improve their health, stress and quality of life and believes massage therapy is a vital part of overall health and wellness.

A seasoned practitioner, she understands that each patient comes to her with a unique story. Anita enjoys talking with patients to better understand their concerns and developing personalized treatment plans to address their individual wellness goals. Her treatment plans include effective massage techniques to increase relaxation, reduce stress and pain, and have patients back to performing their daily activities. Anita enjoys working with chiropractors and other professionals to create a holistic approach for each patient.

She is experienced in a variety of massage types, including Swedish, deep tissue, prenatal, sports, oncology, therapeutic and integrated massage, as well as trigger point therapy.

Anita is licensed by the State of Michigan and is board-certified by the National Certification Board for Therapeutic Massage and Bodywork. She received her associates degree in Health Science from Baker College.

Licensed Massage Therapist (LMT)

Erin Covert is a board-certified, licensed massage therapist and meditation instructor at the Henry Ford Center for Integrative Medicine. As a seasoned practitioner of integrative medicine, she is committed to providing the best and safest treatments to support the bodys natural healing mechanisms. She believes that mental and physical relaxation can greatly contribute to anyones overall healing experience.

An experienced practitioner, Erin has been providing massage therapy for more than 15 years in a variety of settings. She caters each session to her patients unique needs and uses a variety of techniques to achieve the desired result. With advanced training in therapeutic work, relaxation, deep muscle, neuromuscular techniques, trigger point therapy, Reiki, sports massage, prenatal, and geriatric massage, her specialty is in treating neck and shoulder issues, pain conditions, and stress.

As a life-long wellness and natural-healing enthusiast, Erin began practicing yoga and meditation at age 14. She also currently teaches meditation classes to help promote mental and physical relaxation as well as mindfulness in her students.

Erin is licensed by the State of Michigan and board-certified by the National Certification Board for Therapeutic Massage and Bodywork. She received her Bachelors of Applied Science in Massage Therapy from Siena Heights University. She is recognized as a Master Bodywork Practitioner by the Health Enrichment Center School of Therapeutic Massage. Erin is also a level II reiki practitioner. She is currently completing her meditation instructor certification from the American Institute for Health Care Professionals (AIHCP).

Licensed Massage Therapist (LMT)

Lamiita Cical, LMT is a board-certified, licensed massage therapist at the Henry Ford Center for Integrative Medicine. As a practitioner of integrative medicine, Lamiita believes in the numerous health benefits of massage and is committed to promoting optimal wellness in all of her patients. Lamiitas belief is that increased relaxation or stress and pain relief can be achieved through personalized massage therapy.

With more than 15 years of experience in massage therapy, Lamiita is very knowledgeable on a wide variety of massage modalities, including reflexology, Swedish massage, prenatal massage, sport massage, lymphatic massage, deep tissue massage, and geriatric massage.

Lamiita is licensed by the State of Michigan and board-certified by the National Certification Board for Therapeutic Massage and Bodywork. She attended the University of Timisoara in Romania before graduating with academic excellence from the High Tech Institute of Minnesota, a health-career school that offers training programs specifically for massage therapists and medical assistants.

Read more:
Center for Integrative Medicine Team - Detroit, MI

Read More...

Genetic Engineering Products | Boundless Microbiology

February 20th, 2019 9:45 pm

Overview of Biotechnology

Biotechnology is the use of biological techniques and engineered organisms to make products or plants and animals that have desired traits.

Describe the historical development of biotechnology

Biotechnology: Brewing (fermentation of beer) was an early application of biotechnology.

People have used biotechnology processes, such as selectively breeding animals and fermentation, for thousands of years. Late 19th and early 20th century discoveries of how microorganisms carry out commercially useful processes and how they cause disease led to the commercial production of vaccines and antibiotics. Improved methods for animal breeding have also resulted from these efforts. Scientists in the San Francisco Bay Area took a giant step forward with the discovery and development of recombinant DNA techniques in the 1970s. The field of biotechnology continues to accelerate with new discoveries and new applications expected to benefit the economy throughout the 21st century.

In its broadest definition, biotechnology is the application of biological techniques and engineered organisms to make products or modify plants and animals to carry desired traits. This definition also extends to the use of various human cells and other body parts to produce desirable products. Bioindustry refers to the cluster of companies that produce engineered biological products and their supporting businesses. Biotechnology refers to the use of the biological sciences (such as gene manipulation), often in combination with other sciences (such as materials sciences, nanotechnology, and computer software), to discover, evaluate and develop products for bioindustry. Biotechnology products have made it easier to detect and diagnose illnesses. Many of these new techniques are easier to use and some, such as pregnancy testing, can even be used at home. More than 400 clinical diagnostic devices using biotechnology products are in use today. The most important are screening techniques to protect the blood supply against contamination by AIDS and the hepatitis B and C viruses.

Genetic engineering means the manipulation of organisms to make useful products and it has broad applications.

Describe the major applications of genetic engineering

Genetic engineering, also called genetic modification, is the direct manipulation of an organisms genome using biotechnology.

New DNA may be inserted in the host genome by first isolating and copying the genetic material of interest, using molecular-cloning methods to generate a DNA sequence; or by synthesizing the DNA, and then inserting this construct into the host organism. Genes may be removed, or knocked out, using a nuclease.

Genetically manipulated mice: Laboratory mice are genetically manipulated by deleting a gene for use in biomedical research.

Gene targeting is a different technique that uses homologous recombination to change an endogenous gene, and can be used to delete a gene, remove exons, add a gene, or introduce point mutations. Genetic engineering has applications in medicine, research, industry and agriculture and can be used on a wide range of plants, animals and microorganisms.

Genetic engineering has produced a variety of drugs and hormones for medical use. For example, one of its earliest uses in pharmaceuticals was gene splicing to manufacture large amounts of insulin, made using cells of E. coli bacteria. Interferon, which is used to eliminate certain viruses and kill cancer cells, also is a product of genetic engineering, as are tissue plasminogen activator and urokinase, which are used to dissolve blood clots.

Another byproduct is a type of human growth hormone; its used to treat dwarfism and is produced through genetically-engineered bacteria and yeasts. The evolving field of gene therapy involves manipulating human genes to treat or cure genetic diseases and disorders. Modified plasmids or viruses often are the messengers to deliver genetic material to the bodys cells, resulting in the production of substances that should correct the illness. Sometimes cells are genetically altered inside the body; other times scientists modify them in the laboratory and return them to the patients body.

Since the 1990s, gene therapy has been used in clinical trials to treat diseases and conditions such as AIDS, cystic fibrosis, cancer, and high cholesterol. Drawbacks of gene therapy are that sometimes the persons immune system destroys the cells that have been genetically altered, and also that it is hard to get the genetic material into enough cells to have the desired effect.

Many practical applications of recombinant DNA are found in human and veterinary medicine, in agriculture, and in bioengineering.

Describe the advances made possible by recombinant DNA technology

Recombinant DNA technology is the latest biochemical analysis that came about to satisfy the need for specific DNA segments. In this process, surrounding DNA from an existing cell is clipped in the desired amount of segments so that it can be copied millions of times.

Construction of recombinant DNA: A foreign DNA fragment is inserted into a plasmid vector. In this example, the gene indicated by the white color is inactivated upon insertion of the foreign DNA fragment.

Recombinant DNA technology engineers microbial cells for producing foreign proteins, and its success solely depends on the precise reading of equivalent genes made with the help of bacterial cell machinery. This process has been responsible for fueling many advances related to modern molecular biology. The last two decades of cloned-DNA sequence studies have revealed detailed knowledge about gene structure as well as its organization. It has provided hints to regulatory pathways with the aid of which gene expression in myriad cell types is controlled by the cells, especially in those organisms having body plan with basic vertebrae structure.

Recombinant DNA technology, apart from being an important tool of scientific research, has also played a vital role in the diagnosis and treatment of various diseases, especially those belonging to genetic disorders.

Some of the recent advances made possible by recombinant DNA technology are:

1. Isolating proteins in large quantities: many recombinant products are now available, including follicle stimulating hormone (FSH), Follistim AQ vial, growth hormone, insulin and some other proteins.

2. Making possible mutation identification: due to this technology, people can be easily tested for mutated protein presence that can lead to breast cancer, neurofibromatosis, and retinoblastoma.

3. Hereditary diseases carrier diagnosis: tests now available to determine if a person is carrying the gene for cystic fibrosis, the Tay-Sachs diseases, Huntingtons disease or Duchenne muscular dystrophy.

4. Gene transfer from one organism to other: the advanced gene therapy can benefit people with cystic fibrosis, vascular disease, rheumatoid arthritis and specific types of cancers.

Bacterial genetics can be manipulated to allow for mammalian gene expression systems established in bacteria.

Describe the sequence of events in a genetically engineered expression system

Gene expression is the process by which information from a gene is used in the synthesis of a functional gene product. These products are often proteins and are produced after the process of translation. An expression system that is categorized as a genetic engineering product is a system specifically designed for the production of a gene product of choice. This is normally a protein, although may also be RNA, such as tRNA or a ribozyme.

The genetically engineered expression system contains the appropriate DNA sequence for the gene of choice which is engineered into a plasmid that is introduced into a bacteria host. The molecular machinery that is required to transcribe the DNA is derived from the innate and naturally occurring machinery in the host. The DNA is then transcribed into mRNA and then translated into protein products.

In a genetically engineered system, this entire process of gene expression may be induced depending on the plasmid used. In the broadest sense, mammalian gene expression includes every living cell but the term is more normally used to refer to expression as a laboratory tool. An expression system is therefore often artificial in some manner. Viruses and bacteria are an excellent example of expression systems.

The oldest and most widely used expression systems are cell-based. Expression is often done to a very high level and therefore referred to as overexpression. There are many ways to introduce foreign DNA to a cell for expression, and there are many different host cells which may be used for expression. Each expression system also has distinct advantages and liabilities.

Expression systems are normally referred to by the host and the DNA source or the delivery mechanism for the genetic material. For example, common bacterial hosts are E.coli and B. subtilis. With E. coli, DNA is normally introduced in a plasmid expression vector. The techniques for overexpression in E. coli work by increasing the number of copies of the gene or increasing the binding strength of the promoter region so as to assist transcription.

Bacterial Flora: E. coli is one of the most popular hosts for artificial gene expression.

Genetic engineering enables scientists to create plants, animals, and microorganisms by manipulating genes.

Explain the advantages and disadvantages of producing genetically engineered proteins in bacteria

The first successful products of genetic engineering were protein drugs like insulin, which is used to treat diabetes, and growth hormone somatotropin. These proteins are made in large quantities by genetically engineered bacteria or yeast in large bioreactors. Some drugs are also made in transgenic plants, such as tobacco. Other human proteins that are used as drugs require biological modifications that only the cells of mammals, such as cows, goats, and sheep, can provide. For these drugs, production in transgenic animals is a good option. Using farm animals for drug production has many advantages because they are reproducible, have flexible production, are easily maintained, and have a great delivery method (e.g. milk).

Synthetic Insulin: human insulin produced by recombinant DNA technology.

Recombinant DNA technology not only allows therapeutic proteins to be produced on a large scale but using the same methodology protein molecules may be purposefully engineered. Genetic modifications introduced to a protein have many advantages over chemical modifications. Genetically engineered entities are biocompatible and biodegradable. The changes are introduced in 100% of the molecules with the exclusion of rare errors in gene transcription or translation. The preparations do not contain residual amounts of harsh chemicals used in the conjugation process. Bacterial expression systems, due to their simplicity, are often not able to produce a recombinant human protein identical to the naturally occurring wild type. Bacteria did not develop sophisticated mechanisms for performing post-translational modifications that are present in higher organisms. As a consequence, an increasing number of protein therapeutics is expressed in mammalian cells. However the low cost and simplicity of cultivating bacteria is an unbeatable advantage over any other expression system and therefore E. coli is always a preferable choice both on a lab scale and in industry.

Many mammalian proteins are produced by genetic engineering. These include, in particular, an assortment of hormones and proteins for blood clotting and other blood processes. For example, tissue plasminogen activator (TPA) is a blood protein that scavenges and dissolves blood clots that may form in the nal stages of the healing process. TPA is primarily used in heart patients or others suffering from poor circulation to prevent the development of clots that can be life-threatening. Heart disease is a leading cause of death in many developed countries, especially in the United States, so microbially produced TPA is in high demand. In contrast to TPA, the blood clotting factors VII, VIII, and IX are critically important for the formation of blood clots. Hemophiliacs suffer from a deciency of one or more clotting factors and can therefore be treated with microbially produced clotting factors. In the past hemophiliacs have been treated with clotting factor extracts from pooled human blood, some of which was contaminated with viruses such as HIV and hepatitis C, putting hemophiliacs at high risk for contracting these diseases. Recombinant clotting factors have eliminated this problem.

Go here to see the original:
Genetic Engineering Products | Boundless Microbiology

Read More...

Human Genetic Modification | Center for Genetics and Society

February 20th, 2019 9:45 pm

Human genetic modification is the direct manipulation of the genome using molecular engineering techniques. Recently developed techniques for modifying genes are often called gene editing. Genetic modification can be applied in two very different ways: somatic genetic modification and germline genetic modification.

Somatic genetic modification adds, cuts, or changes the genes in some of the cells of an existing person, typically to alleviate a medical condition. These gene therapy techniques are approaching clinical practice, but only for a few conditions, and at a very high cost.

Germline genetic modification would change the genes in eggs, sperm, or early embryos. Often referred to as inheritable genetic modification or gene editing for reproduction, these alterations would appear in every cell of the person who developed from that gamete or embryo, and also in all subsequent generations. Germline modification has not been tried in humans, but it would be, by far, the most consequential type of genetic modification. If used for enhancement purposes, it could open the door to a new market-based form of eugenics. Human germline modification has been prohibited by law in more than 40 countries, and by a binding international treaty of the Council of Europe.

View post:
Human Genetic Modification | Center for Genetics and Society

Read More...

Biomedical Sciences Graduate Program | Biotechnology

February 20th, 2019 12:42 am

Research inBiotechnology at UVA brings togetherresearchers from all biomedical, engineering, and chemical sciences at UVA to promote state-of-the-art collaborative science. From this innovative science comes conceptual breakthroughs and new products.In 2000, we established a Biotechnology Training Program (BTP)at UVAwith the goal of providing fertile ground for the development of future leaders in science and technology. It is one of only 19 BTPs nationwide. Our graduates are scientific leaders at major biotechnology companies, federal agencies, and foundations, and lead independent research labs at universities, or are postdoctoral scientists at institutions nationwide.

The BTP offers many enhancements. The 2 3 month company externship training is transformative. Some students alter career plans towards academia or industrial research. Others affirm prior career directions or receive unexpected offers of employment. All make important contributions, some publish articles, and invariably the collaboration enhances thesis projects. Venues are worldwide, from Boston to San Francisco to Australia, England, Holland, Finland, Germany, Spain and Sweden.

We also offer company tours including Merck, Pfizer, BD; panel discussions with industrial leaders including BTP alumni; as well as seminars and biannual symposia that gather recognized innovators under the umbrella of a broad scientific theme.

Our outstanding mentorsfrom across the sciences at UVA are award-winningleaders in their fields, with success in nurturing the best from our students. Many hold patents, and several have started companies. This is an exciting time for our students to be at the frontlines of science and technology.

Go here to see the original:
Biomedical Sciences Graduate Program | Biotechnology

Read More...

Longevity – SNPedia

February 18th, 2019 9:45 pm

Research on longevity, which can also be thought of as maximal lifespan, is more popularly associated with extending human life than with the more strict connotation of life expectancy (more at Wikipedia). Heredity and other factors (such as birth order and age of the mother at the time of the person's birth) influence longevity. [1]

There are at least 3 potentially overlapping classes of SNPs (or other genetic polymorphisms) that can be considered to affect longevity. First, many SNPs may influence susceptibility to diseases that shorten longevity; these can be found in SNPedia associated with those diseases, and related information is summarized on the heritability page. Second, some SNPs are being discovered based on their prevalence in people who live beyond average human lifespan; these SNPs may enhance longevity. Third, certain SNPs may be to able to affect longevity only in certain environmental contexts, for example SNPs that shorten or lengthen longevity only if an individual with a given genotype is also exposed to certain diets or toxins (such as cigarette smoke).

SNPs from the latter two categories include:

A 2017 GWAS analysis of parental longevity in 300,000 UK Biobank participants of European descent found 10+ SNPs to be associated with combined mothers' and fathers' attained age (and a few others just with paternal or maternal age); these 10+ SNPs and the longevity-associated allele were [PMID 29227965]:

Overall, it's useful to realize that SNPs are likely to influence your risk of dying from 9 of the top 10 causes of death (in developed countries), as noted below (based on 2000 US data):

10.1126/science.1190532 identified 150 snps however numerous questions about the plausibility of the results, led to it's eventual retraction.

http://genomics.senescence.info/download.html

More here:
Longevity - SNPedia

Read More...

Can Stem Cells Stop Aging? – Medical News Bulletin …

February 18th, 2019 9:44 pm

Aging is a natural process that is the cumulative effect of genetic and environmental damage to our bodies and DNA. Stem cells found within the body help to combat the effects of aging. Researchers in the US have summarized the research to date concerning how stem cells and anti-aging genes impact the process of aging.

Aging is the unavoidable consequence of living, which may bring a host of health problems. Loss of hearing, vision, muscle strength, bone mass, immunity, cognition, and metabolism are just a few of the issues aging causes. Cumulatively, these health issues impact the society, the economy, and the health care system. Although we cope with these issues through shared programs such as senior housing, retirement savings, and Medicare, they do not cure but merely treat the health problems associated with aging.

Aging is a natural progressive development that is controlled by genetic and environmental factors. These factors negatively or positively affect our bodies to increase or decrease the aging process within our bodies. The accumulation of these factors will ultimately affect the stem cells within our bodies, which can be considered the essential building blocks of our bodies. Stem cells do not typically do work in our bodies, unlike muscle cells that are used for running or neurons within our brain for thinking. Instead, stem cells have the special ability to create copies of themselves and transform into other types of cellssuch as muscle cells or neurons which is the basis of body regeneration.

Stem cells could be considered the key to regulating our aging. Since aging is the natural deterioration of our bodies, stem cells help regenerate our bodies by replacing old cells that are too deteriorated to work or damaged beyond self-help. This is seen most prominently within other animals such as those belonging to thePlanaria genus, which can regenerate their entire bodies in five days, and Hydra, which can also regenerate their entire bodies in seven to ten days. Salamanders can also regenerate their limbs within just a few days.

Although humans do not share the same extent of regeneration, we do have the capacity of regenerating over 2/3 of our livers as well as the entire tips of our fingers at a young age. However, our regeneration is more apparent in healing our bodies from the daily traumas we endure such as environmental pollutants, smoking, drinking, stress, social burden, and depression. A recent review in the journal Stem Cell Research and Therapy summarizes what we know so far about stem cells and aging.

In conjunction with stem cells, genetics play a pivotal role in determining how fast we age. Klotho, named after the Greek goddess which controls the thread of life, is one of the most well-studied anti-aging genes. In genetic studies, turning Klotho on increases the lifespan of mice, while turning Klotho off results in premature aging. Researchers have shown Klotho controls many elements of aging such tissue oxidation, insulin levels, and stem cell regeneration.

Telomere length has been shown to be highly associated with body age. Telomeres are the end-caps of DNA that protect them from being damaged. The longer your telomeres are, the younger your body is. Normally, we are all born with long telomeres, however, as we age our telomeres begin to shorten. Indeed, telomere shortening has been known to be a cause of stem cell senescence (deactivation) and subsequent death.

To combat telomere shortening, our bodies employ an enzyme called telomerase to maintain telomere length as we age. However, telomerase activity also diminishes with age which limits its anti-aging capabilities. Interestingly, calorie restriction has been shown increase telomerase activity and maintain telomere length. Lowering calorie intake by 30% increases lifespan by 30%. Calorie restriction in animal models have shown to have beneficial effects on counteracting oxidation, inflammation, detoxification, telomerase activity, and DNA repair. This phenomenon has been consistent across all animals tested of all complexity suggesting a fundamental link between diet and aging. For ethical reasons, this has never been proven in humans and is not condoned by physicians.

The goal of many current anti-aging treatments is to increase the health and population of stem cells within the body to better counteract the effects of aging through regeneration. One type of stem cell that is of keen interest to researchers and pharmaceutical companies are mesenchymal stem cells (MSC). These stem cells have been shown to be a core factor in skin, muscle, cartilage, and bone regeneration. Normally, MSC is found in the bone marrow. When the body is injured (e.g. skin cut), cytokines, which are chemical signals used by the body to communicate, are released to activate MSC and travel to the injured area for repair.

However, as we age the number of mesenchymal stem cells within our bone marrow will deplete which slows down our regeneration causing us to age. This is most apparent within our skin which deteriorates over time causing loss of elasticity, sagging, and wrinkling. Pharmaceutical companies are interested in harvesting certain growth factors, which are found naturally within our body, to supplement into skin care products. This will hopefully cause the mesenchymal stem cell population within the skin to multiply which will increase our bodys natural skin regeneration.

Aging is a natural process that is the cumulative effect of genetic and environmental damage to our bodys and DNA. Stem cells found naturally within our body help to combat the effects of aging, but degrade over time due to factors such as telomerase decline. Though researchers and pharmaceuticals have shown ways to extend lifespans through genetic and diet alterations, the goal of halting aging altogether seems distant. However, a new wave of anti-aging products, medical advancements, and a better understanding of diet may be able to slow down the aging process and give us more exciting and youthful years.

Written byAaron Kwong, MSc

References:

(1) Ullah, M. & Sun, Z. Stem cells and anti-aging genes: double-edged sworddo the same job of life extension. Stem Cell Res. Ther.9, 3 (2018).(2) Shieh, S.-J. & Cheng, T.-C. Regeneration and repair of human digits and limbs: fact and fiction. Regen. (Oxford, England)2, 14968 (2015).(3) Ogoke, O., Oluwole, J. & Parashurama, N. Bioengineering considerations in liver regenerative medicine. J. Biol. Eng.11, 46 (2017).(4) Heilbronn, L. K. & Ravussin, E. Calorie restriction and aging: review of the literature and implications for studies in humans 1 3. (2003).

See original here:
Can Stem Cells Stop Aging? - Medical News Bulletin ...

Read More...

Olivia Colman’s heartfelt appeal for stem cell donors …

February 18th, 2019 9:44 pm

BAFTA winner Olivia Colman has made a heartfelt appeal for people to donate stem cells after losing her school friend to blood cancer.

The Favourite actress revealed how a transplant gave classmate Pip hope in the darkness.

In a video for the charity Anthony Nolan, the star describes how her friend, who was diagnosed with leukaemia at the age of 31, didnt make it.

Colman urges the public to sign up to the charitys stem cell register, which she and husband Ed Sinclair joined in 2008, so that others have a chance of living. In the film, she says: Sadly my friend Pip didnt make it, but together we can make sure more people like Pip do make it. We want more people on the register. Its just a little swab of the mouth Without you there is no cure.

Pips only chance of survival had been a donor who could provide a perfect match, according to Colman. Soon a donor was found in Australia. Anthony Nolan did an amazing thing, Colman said. She became patron of Anthony Nolan in July last year.

About 2,000 people in the UK need a stem cell transplant every year. Donations from young men and people with black, Asian and ethnic minority backgrounds are needed in particular.

Anthony Nolans chief executive Henny Braund said: It is wonderful to have Olivias support and I am grateful to her for sharing this heartfelt story. This will help us continue to give hope to thousands of people every year.

Read the rest here:
Olivia Colman's heartfelt appeal for stem cell donors ...

Read More...

Regenerative Medicine | Swedish Medical Center Seattle and …

February 18th, 2019 9:42 pm

Regenerative medicine (platelet rich plasma, stem cell treatment and tenex) is a non-surgical and natural treatment to stimulate and enhance healing of injuries, such as osteoarthritis, tendinitis, plantar fasciitis, and degenerative musculoskeletal diseases.

Most simply defined, PRP is a platelet count above normal. Platelets are your bodys natural healing particles. When you get an injury, platelets in your blood go to the area of injury. Your platelets release growth factors (programming signals) that tell your brain you have an injury and what type of stem cells to send to the area so you get an appropriate healing response. Once concentrated out of a larger volume of blood, PRP can be injected under ultrasound guidance into the injured area to stimulate and enhance healing. PRP has been shown to be beneficial on conditions such as tendinitis/tendinosis, tendon tears, ligament sprains/tears, muscle tears, and osteoarthritis/ joint pain. PRP can also be used in the spine, where the injections are placed using x-ray guidance after careful confirmation that those structures are indeed the source of pain.

This process involves harvesting your stem cells from your bone marrow in your pelvis and concentrating the stem cells by processing the bone marrow in a specialized centrifuge. After first numbing the area so it isnt painful, a needle is used to withdraw bone marrow from your posterior iliac crest (lower back area). This is the same procedure performed for over 50 years in hematology offices. Special centrifuges are then used to spin the bone marrow and separate out and concentrate the stem cells. The stem cells are then activated with platelet rich plasma (PRP) and injected under ultrasound guidance into damaged tissue or joints. Some of the most common applications of stem cell treatments are for osteoarthritis, avascular necrosis, tendon and ligament sprains/tears, tendinitis/tendinosis labral tears, and muscle tears. Stem cells can also be used in the spine, where the injections are placed using x-ray guidance after careful confirmation that those structures are indeed the source of pain.

Recently, percutaneous ultrasonic tenotomy (UT) has evolved as a potential minimally invasive treatment for tendinopathy. This has been performed at Swedish sports medicine since 2014. It is a novel technique in which phacoemulsification (sound waves) are used to debride (clean up) and aspirate bad tendon tissue through a small incision via a small handpiece. Studies have shown it to be safe and effective at treating tendinopathies in multiple different tendons, including documentation of success in treatment of plantar fasciopathy after previous release. It is most commonly used on Achilles tendinitis, lateral epicondylitis (tennis elbow), medial epicondylitis (golfers elbow), plantar fasciitis/ plantar fascial rupture, patellar tendinitis, quadriceps tendinitis, calcific tendinitis of the shoulder, gluteal tendinitis, and hamstring tendinitis.

More here:
Regenerative Medicine | Swedish Medical Center Seattle and ...

Read More...

Global Regenerative Medicine Market Analysis & Forecast to …

February 18th, 2019 9:42 pm

NEW YORK, Feb. 14, 2019 /PRNewswire/ -- This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was worth $28 billion in 2018 and will grow to over $81 billion by 2023, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2023. Tissue engineering is forecast to grow at a CAGR of x% to 2023 and potentially reach $x billion. This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 700 pages.

Read the full report: https://www.reportlinker.com/p04876076

An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies. Global regenerative medicine market, global breakdown, application breakdown and leading market players Detailed account of the stem cell industry market by geography, indication and company profiles Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies. Insight into the biobanking industry globally and its impact on the overall market Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective SWOT analysis of the global market Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe

Key Questions Answered

What is the global market for regenerative medicine from 2017 to 2023? What is the global market for regenerative medicine by geography, through 2023? What is the global market for regenerative medicine by indication, through 2023? What is the global market for the stem cell industry from 2017 to 2023? What is the global market for the stem cell industry by geography, through 2023? What is the global market for the stem cell industry by indication, through 2023? What disruptive technology is advancing the overall regenerative medicine market? What are the major company players in the regenerative medicine, stem cells, tissue engineering and CAR-T industries? What types of clinical trials are currently being performed by stakeholders and major players? What are the strengths, weaknesses, opportunities and threats to the market? Which geographic markets are dominating the space? What are the advantages and disadvantages of the allogenic and autologous stem cell industry? What are the main driving forces of this space? What are the main restraints of the regenerative medicine industry as a whole? What is the current environment of the global cord blood bank industry? What are the global access challenges of the regenerative medicine market? What is the space like in Japan, China, South Korea, USA and Europe? What are the main challenges associated with CAR T therapy? When will the first CAR T therapeutics be approved? What are the current regulations for immunotherapies in USA, Europe & Japan? What are the main manufacturing steps in CAR T therapy? What challenges lie ahead for CAR T production?

Countries Covered Global, USA, Europe, UK, Japan, South Korea, Singapore, Asia/Pacific, ROC

Executive Summary

Regenerative medicine's main objective is to heal and replace organs/cells that have been damaged by age, trauma or disease. Congenital defects can also be addressed with regenerative medicine. Therefore, it's market encompasses dermal wounds, cardiovascular disease, specific cancer types and organ replacement. To that end, regenerative medicine is a broader field and manipulates the body's immune system and regeneration potential to achieve its requirement. Financially speaking, investment into this space is dominated by grants, private investors and publicly traded stocks. Looking forward, the regenerative medicine market is promising for a number of robust reasons including:

Increasing number of potentially successful clinical trials Increasing number of mergers and acquisitions High unmet need in many indications Global penetration, especially in Japan will boost the market

Of course restrictions to this market include strict regulations in certain geographies, and also the level of investment required to support R&D, clinical research, trials and commercialization. Reimbursement strategies are also paramount to success of the overall space.

There are over 700 regenerative medicine companies globally at present, that all together have a $x billion market cap. At present the total regenerative medicine market has more than 500 products commercialized. The regenerative medicine market encompasses a number of key technology submarkets including: Cell therapy including stem cells Tissue Engineering Biomaterials BioBanking

Reconstructive surgeries for bones and joints is the mainstay of the regenerative medicine market. Geographically speaking, due to the dominance of the bone and joint reconstruction market, the US has the biggest space. This is followed by Europe. However, due to recent positive legislation in Japan and Europe, the stem cell arena will grow more substantially in these regions over the next five years. By 2023, it is possible that Europe will surpass the US market with respect to stem cell applications, and this will become more likely if the Trump Administration restricts legislation and funding.

Market Applications & Opportunities for Regenerative TherapiesRegenerative medicine, including cellular and gene therapies will have a significant impact on the expenditure of payers, once reimbursement schemes are optimized. To that end a number of conditions that regenerative medicine tackles is synonymous with an aging population such as Cardiovascular diseases & stroke Diabetes Inflammatory and immune diseases Wound healing and soft tissue regeneration Neurodegenerative diseases e.g., ALS, Alzheimer's and Parkinson's Spinal cord injury Musculoskeletal disorders Ocular disease

Global Financial LandscapeThe last few years have been busy for regeneration medicine, cellular therapeutics and the gene therapy industry, with high investment from pharma giants such as Eli Lilly, BMS, Astra Zeneca and Sanofi. Company partnerships were also in motion that included Kite Pharma and Bluebird/Five Prime, Juno and Fate Therapeutics/ Editas Medicine. One of the highlights was the $x billion, four year deal between CRISPR Technologies and Vertex which indicated that gene editing technologies are cutting edge.

Stem Cell Market Analysis & Forecast to 2023Today the stem cell and regenerative medicine industries are interlinked and over the last number of years have grown substantially. Regenerative medicine replaces or regenerates cells, tissues or organs and in order to achieve this uses produces from the pharmaceutical, biologics, medical device and cell therapy spaces. Therefore, cell therapy, and stem cells come under the umbrella market of regenerative medicine. Cell therapy is a platform by which regenerative medicine can achieve its aim and concentrates on using cells as therapeutics to treat disease. In 2018, the global stem cell market was worth $x billion globally, and this is set to rise to $x billion by 2023 with a CAGR of x%.

Tissue Engineering Market Analysis and Forecast to 2023Tissue engineering was the forerunner of the present regenerative medicine market. The area of biomaterials was developed to use cells and biological material and incorporate them into scaffolds and functional tissues. Some of the main applications of tissue engineered products include artificial skin and cartilage and so this area dominates the dermatology, bone and joint submarket. Wound repair is also a significant area for tissue engineering, with products such as Dermagraft in the market.

The global market for tissue engineering was estimated at $x billion in 2018 by Kelly Scientific analysis. It is forecast to grow at a CAGR of x% to 2023 and potentially reach $x billion. Tissue engineering is being driven by the increase in technology of biomaterials, bioscaffolds and bio 3D printing. The rise in the amount of orthopedic transplantations is demanding the market to produce more innovative solutions such as 3D printed organs. In the long term future, Kelly Scientific forecasts the advance of cutting edge 3D bioprinters in this market place

Biobanking Market AnalysisThe biobanking industry is made up of over 500 public and private blood banks globally. These companies and institutions collect, store and distribute adipose tissue, cord blood and birth tissues, musculoskeletal tissues, pericardium, skin, bone, vascular tissue, autologous and allogeneic cells and other biological samples. They operate by charging a collection fee and then a storage fee, which is usually operational for 20 years. Private banking costs between $1,350 to $2,300 as an initial fee, and then between $100 to $175 per annum for storage. Public banking is free, and a number of hybrid models have been introduced in Europe and Asia to date.

CAR-T IndustryThe CAR-T industry is addressing unmet needs in specific relapsed cancers, however does early clinical trial data support a blockbuster status for this upcoming therapy? Some patients do indeed show long term activity and high remission rates, but there is a large proportion of patients with toxicities such as cytokine release syndrome and neurotoxicity. The main players within the CAR-T market are Juno Therapeutics, Kite Pharma, Novartis and Cellectis. The market is moving ahead, backed by years of R&D, from both academia and industry, investors capitol and small clinical studies. From 2017, Kelly Scientific forecasts that CAR T therapy will become more streamlined, with faster manufacturing times as advances in technologies take hold and clinical trials provide more robust evidence that this immunotherapy is robust. These factors, plus strategies to reduce adverse reactions and toxicities and larger players like Novartis taking stage will push CAR T therapy ahead. However, recent deaths in the Juno ROCKET trial are creating questions amongst investors. How will the CAR T space influence the total immunotherapy industry going forward? This comprehensive report scrutinizes the total market and provides cutting-edge insights and analysis.

Read the full report: https://www.reportlinker.com/p04876076

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Story continues

View post:
Global Regenerative Medicine Market Analysis & Forecast to ...

Read More...

Human cloning – Wikipedia

February 18th, 2019 2:41 am

Human cloning is the creation of a genetically identical copy (or clone) of a human. The term is generally used to refer to artificial human cloning, which is the reproduction of human cells and tissue. It does not refer to the natural conception and delivery of identical twins. The possibility of human cloning has raised controversies. These ethical concerns have prompted several nations to pass laws regarding human cloning and its legality.

Two commonly discussed types of theoretical human cloning are: therapeutic cloning and reproductive cloning. Therapeutic cloning would involve cloning cells from a human for use in medicine and transplants, and is an active area of research, but is not in medical practice anywhere in the world, as of April2017[update]. Two common methods of therapeutic cloning that are being researched are somatic-cell nuclear transfer and, more recently, pluripotent stem cell induction. Reproductive cloning would involve making an entire cloned human, instead of just specific cells or tissues.

Although the possibility of cloning humans had been the subject of speculation for much of the 20th century, scientists and policy makers began to take the prospect seriously in the mid-1960s.

Nobel Prize-winning geneticist Joshua Lederberg advocated cloning and genetic engineering in an article in The American Naturalist in 1966 and again, the following year, in The Washington Post.[1] He sparked a debate with conservative bioethicist Leon Kass, who wrote at the time that "the programmed reproduction of man will, in fact, dehumanize him." Another Nobel Laureate, James D. Watson, publicized the potential and the perils of cloning in his Atlantic Monthly essay, "Moving Toward the Clonal Man", in 1971.[2]

With the cloning of a sheep known as Dolly in 1996 by somatic cell nuclear transfer (SCNT), the idea of human cloning became a hot debate topic.[3] Many nations outlawed it, while a few scientists promised to make a clone within the next few years. The first hybrid human clone was created in November 1998, by Advanced Cell Technology. It was created using SCNT - a nucleus was taken from a man's leg cell and inserted into a cow's egg from which the nucleus had been removed, and the hybrid cell was cultured, and developed into an embryo. The embryo was destroyed after 12 days.[4]

In 2004 and 2005, Hwang Woo-suk, a professor at Seoul National University, published two separate articles in the journal Science claiming to have successfully harvested pluripotent, embryonic stem cells from a cloned human blastocyst using somatic-cell nuclear transfer techniques. Hwang claimed to have created eleven different patent-specific stem cell lines. This would have been the first major breakthrough in human cloning.[5] However, in 2006 Science retracted both of his articles on clear evidence that much of his data from the experiments was fabricated.[6]

In January 2008, Dr. Andrew French and Samuel Wood of the biotechnology company Stemagen announced that they successfully created the first five mature human embryos using SCNT. In this case, each embryo was created by taking a nucleus from a skin cell (donated by Wood and a colleague) and inserting it into a human egg from which the nucleus had been removed. The embryos were developed only to the blastocyst stage, at which point they were studied in processes that destroyed them. Members of the lab said that their next set of experiments would aim to generate embryonic stem cell lines; these are the "holy grail" that would be useful for therapeutic or reproductive cloning.[7][8]

In 2011, scientists at the New York Stem Cell Foundation announced that they had succeeded in generating embryonic stem cell lines, but their process involved leaving the oocyte's nucleus in place, resulting in triploid cells, which would not be useful for cloning.[10][11]

In 2013, a group of scientists led by Shoukhrat Mitalipov published the first report of embryonic stem cells created using SCNT. In this experiment, the researchers developed a protocol for using SCNT in human cells, which differs slightly from the one used in other organisms. Four embryonic stem cell lines from human fetal somatic cells were derived from those blastocysts. All four lines were derived using oocytes from the same donor, ensuring that all mitochondrial DNA inherited was identical. A year later, a team led by Robert Lanza at Advanced Cell Technology reported that they had replicated Mitalipov's results and further demonstrated the effectiveness by cloning adult cells using SCNT.[3][12]

In 2018, the first successful cloning of primates using somatic cell nuclear transfer, the same method as Dolly the sheep, with the birth of two live female clones (crab-eating macaques named Zhong Zhong and Hua Hua) was reported.[13][14][15][16][17].

In somatic cell nuclear transfer ("SCNT"), the nucleus of a somatic cell is taken from a donor and transplanted into a host egg cell, which had its own genetic material removed previously, making it an enucleated egg. After the donor somatic cell genetic material is transferred into the host oocyte with a micropipette, the somatic cell genetic material is fused with the egg using an electric current. Once the two cells have fused, the new cell can be permitted to grow in a surrogate or artificially.[18] This is the process that was used to successfully clone Dolly the sheep (see section on History in this article).[3]

Creating induced pluripotent stem cells ("iPSCs") is a long and inefficient process. Pluripotency refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous tissue).[19] A specific set of genes, often called "reprogramming factors", are introduced into a specific adult cell type. These factors send signals in the mature cell that cause the cell to become a pluripotent stem cell. This process is highly studied and new techniques are being discovered frequently on how to better this induction process.

Depending on the method used, reprogramming of adult cells into iPSCs for implantation could have severe limitations in humans. If a virus is used as a reprogramming factor for the cell, cancer-causing genes called oncogenes may be activated. These cells would appear as rapidly dividing cancer cells that do not respond to the body's natural cell signaling process. However, in 2008 scientists discovered a technique that could remove the presence of these oncogenes after pluripotency induction, thereby increasing the potential use of iPSC in humans.[20]

Both the processes of SCNT and iPSCs have benefits and deficiencies. Historically, reprogramming methods were better studied than SCNT derived embryonic stem cells (ESCs). However, more recent studies have put more emphasis on developing new procedures for SCNT-ESCs. The major advantage of SCNT over iPSCs at this time is the speed with which cells can be produced. iPSCs derivation takes several months while SCNT would take a much shorter time, which could be important for medical applications. New studies are working to improve the process of iPSC in terms of both speed and efficiency with the discovery of new reprogramming factors in oocytes.[citation needed] Another advantage SCNT could have over iPSCs is its potential to treat mitochondrial disease, as it utilizes a donor oocyte. No other advantages are known at this time in using stem cells derived from one method over stem cells derived from the other.[21]

Work on cloning techniques has advanced our basic understanding of developmental biology in humans. Observing human pluripotent stem cells grown in culture provides great insight into human embryo development, which otherwise cannot be seen. Scientists are now able to better define steps of early human development. Studying signal transduction along with genetic manipulation within the early human embryo has the potential to provide answers to many developmental diseases and defects. Many human-specific signaling pathways have been discovered by studying human embryonic stem cells. Studying developmental pathways in humans has given developmental biologists more evidence toward the hypothesis that developmental pathways are conserved throughout species.[22]

iPSCs and cells created by SCNT are useful for research into the causes of disease, and as model systems used in drug discovery.[23][24]

Cells produced with SCNT, or iPSCs could eventually be used in stem cell therapy,[25] or to create organs to be used in transplantation, known as regenerative medicine. Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplantation is a widely used form of stem cell therapy.[26] No other forms of stem cell therapy are in clinical use at this time. Research is underway to potentially use stem cell therapy to treat heart disease, diabetes, and spinal cord injuries.[27][28] Regenerative medicine is not in clinical practice, but is heavily researched for its potential uses. This type of medicine would allow for autologous transplantation, thus removing the risk of organ transplant rejection by the recipient.[29] For instance, a person with liver disease could potentially have a new liver grown using their same genetic material and transplanted to remove the damaged liver.[30] In current research, human pluripotent stem cells have been promised as a reliable source for generating human neurons, showing the potential for regenerative medicine in brain and neural injuries.[31]

In bioethics, the ethics of cloning refers to a variety of ethical positions regarding the practice and possibilities of cloning, especially human cloning. While many of these views are religious in origin, the questions raised by cloning are faced by secular perspectives as well. Human therapeutic and reproductive cloning are not commercially used; animals are currently cloned in laboratories and in livestock production.

Advocates support development of therapeutic cloning in order to generate tissues and whole organs to treat patients who otherwise cannot obtain transplants,[32] to avoid the need for immunosuppressive drugs,[33] and to stave off the effects of aging.[34] Advocates for reproductive cloning believe that parents who cannot otherwise procreate should have access to the technology.[35]

Opposition to therapeutic cloning mainly centers around the status of embryonic stem cells, which has connections with the abortion debate.[36]

Some opponents of reproductive cloning have concerns that technology is not yet developed enough to be safe - for example, the position of the American Association for the Advancement of Science as of 2014[update],[37] while others emphasize that reproductive cloning could be prone to abuse (leading to the generation of humans whose organs and tissues would be harvested),[38][39] and have concerns about how cloned individuals could integrate with families and with society at large.[40][41]

Religious groups are divided, with some[which?] opposing the technology as usurping God's role in creation and, to the extent embryos are used, destroying a human life; others support therapeutic cloning's potential life-saving benefits.[42][43]

In 2015 it was reported that about 70 countries had banned human cloning.[44]

Human cloning is banned by the Presidential Decree 200/97 of 7 March 1997.[45]

Australia has prohibited human cloning,[46] though as of December2006[update], a bill legalizing therapeutic cloning and the creation of human embryos for stem cell research passed the House of Representatives. Within certain regulatory limits, and subject to the effect of state legislation, therapeutic cloning is now legal in some parts of Australia.[47]

Canadian law prohibits the following: cloning humans, cloning stem cells, growing human embryos for research purposes, and buying or selling of embryos, sperm, eggs or other human reproductive material.[48] It also bans making changes to human DNA that would pass from one generation to the next, including use of animal DNA in humans. Surrogate mothers are legally allowed, as is donation of sperm or eggs for reproductive purposes. Human embryos and stem cells are also permitted to be donated for research.[citation needed]

There have been consistent calls in Canada to ban human reproductive cloning since the 1993 Report of the Royal Commission on New Reproductive Technologies. Polls have indicated that an overwhelming majority of Canadians oppose human reproductive cloning, though the regulation of human cloning continues to be a significant national and international policy issue. The notion of "human dignity" is commonly used to justify cloning laws. The basis for this justification is that reproductive human cloning necessarily infringes notions of human dignity.[49][50][51][52]

Human cloning is prohibited in Article 133 of the Colombian Penal Code.[53]

The European Convention on Human Rights and Biomedicine prohibits human cloning in one of its additional protocols, but this protocol has been ratified only by Greece, Spain and Portugal. The Charter of Fundamental Rights of the European Union explicitly prohibits reproductive human cloning. The charter is legally binding for the institutions of the European Union under the Treaty of Lisbon and for member states of the Union implementing EU law.[54][55]

India does not have specific law regarding cloning but has guidelines prohibiting whole human cloning or reproductive cloning. India allows therapeutic cloning and the use of embryonic stem cells for research proposes.[56][57]

The Federal Assembly of Russia introduced the Federal Law N 54-FZ "On the temporary ban on human cloning" in April 19, 2002. On May 20, 2002 President Vladimir Putin signed this moratorium on the implementation of human cloning. On March 29, 2010 The Federal Assembly introduced second revision of this law without time limit.[58]

Human cloning is explicitly prohibited in Article 24, "Right to Life" of the 2006 Constitution of Serbia.[59]

In terms of section 39A of the Human Tissue Act 65 of 1983,[60] genetic manipulation of gametes or zygotes outside the human body is absolutely prohibited. A zygote is the cell resulting from the fusion of two gametes; thus the fertilised ovum. Section 39A thus prohibits human cloning.[citation needed]

On January 14, 2001 the British government passed The Human Fertilisation and Embryology (Research Purposes) Regulations 2001[61] to amend the Human Fertilisation and Embryology Act 1990 by extending allowable reasons for embryo research to permit research around stem cells and cell nuclear replacement, thus allowing therapeutic cloning. However, on November 15, 2001, a pro-life group won a High Court legal challenge, which struck down the regulation and effectively left all forms of cloning unregulated in the UK. Their hope was that Parliament would fill this gap by passing prohibitive legislation.[62][63] Parliament was quick to pass the Human Reproductive Cloning Act 2001 which explicitly prohibited reproductive cloning. The remaining gap with regard to therapeutic cloning was closed when the appeals courts reversed the previous decision of the High Court.[64]

The first license was granted on August 11, 2004 to researchers at the University of Newcastle to allow them to investigate treatments for diabetes, Parkinson's disease and Alzheimer's disease.[65] The Human Fertilisation and Embryology Act 2008, a major review of fertility legislation, repealed the 2001 Cloning Act by making amendments of similar effect to the 1990 Act. The 2008 Act also allows experiments on hybrid human-animal embryos.[66]

On December 13, 2001, the United Nations General Assembly began elaborating an international convention against the reproductive cloning of humans. A broad coalition of states, including Spain, Italy, the Philippines, the United States, Costa Rica, and the Holy See sought to extend the debate to ban all forms of human cloning, noting that, in their view, therapeutic human cloning violates human dignity. Costa Rica proposed the adoption of an international convention to ban all forms of human cloning. Unable to reach a consensus on a binding convention, in March 2005 a non-binding United Nations Declaration on Human Cloning, calling for the ban of all forms of human cloning contrary to human dignity, was adopted.[67][68]

The Patients First Act of 2017 (HR 2918, 115th Congress) aims to promote stem cell research, using cells that are ethically obtained, that could contribute to a better understanding of diseases and therapies, and promote the derivation of pluripotent stem cell lines without the creation of human embryos.[69]

In 1998, 2001, 2004, 2005, 2007 and 2009, the US Congress voted whether to ban all human cloning, both reproductive and therapeutic (see Stem Cell Research Enhancement Act). Each time, divisions in the Senate, or an eventual veto from the sitting President (President George W. Bush in 2005 and 2007), over therapeutic cloning prevented either competing proposal (a ban on both forms or on reproductive cloning only) from being passed into law. On March 10, 2010 a bill (HR 4808) was introduced with a section banning federal funding for human cloning.[70] Such a law, if passed, would not have prevented research from occurring in private institutions (such as universities) that have both private and federal funding. However, the 2010 law was not passed.

There are currently no federal laws in the United States which ban cloning completely. Fifteen American states (Arkansas, California, Connecticut, Iowa, Indiana, Massachusetts, Maryland, Michigan, North Dakota, New Jersey, Rhode Island, South Dakota, Florida, Georgia, and Virginia) ban reproductive cloning and three states (Arizona, Maryland, and Missouri) prohibit use of public funds for such activities.[71]

Science fiction has used cloning, most commonly and specifically human cloning, due to the fact that it brings up controversial questions of identity.[72][73] Humorous fiction, such as Multiplicity (1996)[74] and the Maxwell Smart feature The Nude Bomb (1980), have featured human cloning.[75] A recurring sub-theme of cloning fiction is the use of clones as a supply of organs for transplantation. Robin Cook's 1997 novel Chromosome 6 and Michael Bay's The Island are examples of this; Chromosome 6 also features genetic manipulation and xenotransplantation.[76] There is also a series named Orphan Black which follows human clones' stories and experiences as they deal with issues and react to being the property of a chain of scientific institutions.

See original here:
Human cloning - Wikipedia

Read More...

Cornell Career Services: Veterinary Medicine FAQ

February 18th, 2019 2:41 am

Which college should I enroll in?

A student in any undergraduate college at Cornell may enroll in the courses required for entry into veterinary college. Cornell undergraduate applicants to veterinary school are enrolled primarily in the College of Agriculture and Life Sciences with a few in the College of Arts and Sciences, the College of Engineering, and the College of Human Ecology. The appropriate choice depends largely on your other academic and career interests. Students should consult the University's publications for information about the seven colleges at Cornell, reviewing their requirements, majors, and course descriptions.

Back to top

What should I major in?

Veterinary schools do not require or recommend any particular undergraduate major course of study or designated preveterinary program. Cornell does not have a preveterinary major and there is no evidence that admissions committees of veterinary colleges give special consideration to any particular undergraduate education beyond satisfactory completion of the required undergraduate courses; for this reason you are encouraged to pursue your own intellectual interest in an academic major.

For example, a student might major in animal science, biological sciences, natural resources or development sociology in the College of Agriculture and Life Sciences. Or you might major in biological sciences, English, anthropology in the College of Arts and Sciences or nutrition in the College of Human Ecology. You complete the preprofessional core of courses while at the same time receiving a broad education, and exploring other interests and careers. In this way, you leave open the option of pursuing an alternative career. You are also more likely to succeed at and benefit from subjects that interest and stimulate you, and you leave open the option of pursuing an alternative career.

Back to top

What courses should I take?

Veterinary schools, while not requiring or recommending any particular major course of study, do require that particular undergraduate courses be completed. Listed below are the minimum course requirements for admission to the College of Veterinary Medicine at Cornell University. Veterinary Medical School Admission Requirements (VMSAR) contains details for other schools.

English Composition

6 semester credit hours

Biology or Zoology (with laboratory)

6 semester credit hours

Introductory Chemistry (with laboratory)

6 semester credit hours

Organic Chemistry (with laboratory)

6 semester credit hours

Biochemistry

4 semester credit hours

Physics (with laboratory)

6 semester credit hours

General Microbiology (with laboratory)

3 semester credit hours

Back to top

Education for becoming a veterinarian: a wider view

In discussing science courses required for entry to veterinary school, it is important to realize that these are only a part of the total educational picture that veterinary schools consider. It is generally agreed that an applicant must be able to perform well in science, to think like a scientist, and even to enjoy science in order to be a competent veterinarian. Being an educated person with an understanding of human nature and human achievement is equally important to veterinarians, both professionally and personally.

Back to top

What kinds of animal care related experience do I need?

Veterinary medicine is an animal oriented profession. Therefore, your experiences working with different kinds of animals in different settings and your understanding of the veterinary profession are important consideration in the selection process. Such experience could involve breeding, rearing, feeding and showing various kinds of animals including companion animals, livestock, laboratory animals, zoo animals or wildlife. You should be prepared to present evidence of hands-on experience with animals and sufficient contact with the veterinary profession so that the admissions committee can determine that you have some understanding of the duties and responsibilities of a practitioner and the scope of veterinary medicine.

Back to top

What are the acceptance statistics for veterinary schools?

For the classes entering the College of Veterinary Medicine at Cornell University (CVMCU) for the past five years, generally over 20 members of the class were from Cornell. Approximately 100 Cornellians apply to CVMCU each year. No figures are currently available for Cornell students accepted at veterinary schools other than Cornell. Nationally, in 2008 there were over 6,000 applicants to U.S. vet school and over to 2,700 enrolled.

Back to top

What is the current employment outlook for vets?

Seventy-five percent of all veterinarians are in private practice, however, veterinarians are employed by government, business, universities, and the military in a wide variety of research, regulatory, and clinical roles. In 2006 the average starting salary for recent graduates was around $56,000 for small animal to $61,000 for large animal practice. The median annual earnings of veterinarians was $72,000 in 2006. Federally employed veterinarians averaged $84,335 in 2007.

Most enrolled need to borrow to cover veterinary college expenses. In order to be able to get loans, be sure to maintain a good credit rating throughout your college years. In 2006 the mean national indebtedness of veterinary graduates was $90,654.

Back to top

What is Cornell Accelerated BS/DVM Program?

The double registration program between Cornell University and the College of Veterinary Medicine at Cornell University is approved for students in the College of Agriculture and Life Sciences. It enables a qualified student to save one year in pursuit of the Bachelor and D.V.M. degrees. The program is intended for students who have been admitted to the College of Veterinary Medicine after completing three years of undergraduate work and who have made sufficient progress on the Bachelor's Degree requirements. Certain courses taken in the College of Veterinary Medicine can be used to complete those requirements. Questions about the program may be directed to Jennifer Mailey, Director of Admissions, College of Veterinary Medicine at Vet_admissions@cornell.edu

Back to top

What help does Cornell provide for health careers students?

What other resources are available?

A sample of books available in the Career Library, 103 Barnes Hall.

American Animal Hospital Association Accredited Practice Directory American Zoo and Aquarium Membership Directory Career Choices for Veterinarians: Beyond Private Practice, Carin Smith, DVM Careers with Animals, Ellen Shenk Extraordinary Jobs with Animals, Alecia Devantier & Carol Turkington Get Into Veterinary School - Insights by an Admission Expert, Joseph Piekunka Opportunites in Zoo Careers, Sydney J. Butter

Back to top

Continue reading here:
Cornell Career Services: Veterinary Medicine FAQ

Read More...

Genetic engineering could save chocolate from going …

February 16th, 2019 9:42 pm

The world's chocolate supply is dwindling. As our global sweet tooth begins to outpace cocoa production, major chocolate companies like Mars Inc. and Barry Callebaut expect to see an industry deficit of 4.4 billion pounds of chocolate by 2030. And by 2050, the cacao seeds used to make chocolate could be extinct.

As farmers struggle to keep up with demand, Bloomberg reports that the price of chocolate has continued to rise, making popular items like Hershey bars more expensive.

Companies that want to keep costs low have had to sacrifice the flavor of their products. In 2014, Bloomberg's Mark Schatzker predicted that chocolate could follow the path of food items like chicken and strawberries, which have lost some of their flavor in the quest to satisfy demand. According to Schatzker, chocolate could soon become "as tasteless as today's store-bought tomatoes."

To prevent that from happening, the nonprofit coalition of farmers called A Fresh Look released a line of chocolate bars that promote the use of genetically modified organisms (GMOs).

Ethos Chocolate uses sugar derived from GMO beets. A Fresh Look

While the bars, known as Ethos Chocolate, don't contain genetically modified cacao an ingredient that's still being developed and tested they do contain sugar that's derived from GMO beets.

According to A Fresh Look's lead scientist, Rebecca Larson, it's the first time a farmer's group has come together to espouse GMO technology, which has been criticized by environmentalists.

Around 70% of the world's cocoa beans hail from West Africa, with Ghana and Ivory Coast serving as the two largest producers. As global temperatures continue to rise, these nations have seen increasingly dry weather, which can prevent cacao trees from growing.

Cacao trees are also particularly vulnerable to disease.

The International Cocoa Organization (ICCO) reported that diseases and pests have resulted in the loss of 30% to 40% of global cocoa production. The report also noted that cocoa species are susceptible to a disease called frosty pod, which has led to entire cocoa farms being abandoned in Latin America.

In West Africa, swollen shoot virus and black pod have also overtaken cacao trees, resulting in huge financial losses. These diseases are made worse by weather conditions such as floods, droughts, and windstorms.

In addition to placing a strain on chocolate manufacturing companies, the loss of cacao trees can impair the livelihoods of tens of millions of people who depend on them economically.

But genetic modification has the potential to lessen these effects by making crops drought tolerant or insect resistant. Studies have shown that GMO crops can improve crop yield, boost farmers' profits, and even reduce the use of pesticides.

While GMOs could be instrumental in saving the world's chocolate supply, they've often been painted as a risk to human health.

Environmental groups contend that GMO crops are more resistant to herbicides, which may or may not be carcinogenic.

Read more: It's almost impossible to avoid GMOs in these 7 everyday items

The 1,600 farmers that make up A Fresh Look have resisted this argument, saying that GMOs are not only safe to consume, but also require less water and improve our nutrition.

A chocolatier in the Ivory Coast explains how cocoa is processed into chocolate. Sia Kambou/AFP/Getty Images

"There's this idea [among consumers] that everything is as mother nature intended, or it was manufactured in a laboratory," Larson told Business Insider. "[We're] helping people understand that GMOs aren't a scary ingredient in their food, but rather a farming technique."

These findings are supported by numerous scientific organizations. In the last two decades, institutions like the National Academy of Sciences, the American Association for the Advancement of Science, and the European Commission have all publicly stated that GMOs don't present harm to human health.

While plenty of chocolate contains ingredients derived from GMOs like corn syrup and soy lecithin, researchers have been slow to develop a genetically modified version of cacao.

Many chocolate companies still cater to consumer preferences for non-GMO items. Ghirardelli, for instance, has publicly stated its mission to make all recipes GMO-free.

One notable exception is Mars, the company behind M&M's and Snickers, which has teamed up with the University of California Berkeley to develop cacao plants that don't wilt or rot. To achieve this, the research team turned to CRISPR, a gene-editing technology that makes small changes to an organism's DNA.

But it could be some time before GMO cacao makes its way onto shelves.

"It all depends on legislative acceptance in different countries where the cacao is being produced," said Larson.

Some of the nations where people buy the most chocolate, such as Germany, Switzerland, and Austria, have restricted their cultivation of GMO crops.

When it comes to consumers, Larson said her team's pro-GMO stance is already starting to catch on: "We've gotten overwhelming feedback from all kinds of industry groups and consumers saying, 'Hey, it's about time.'"

Read the original:
Genetic engineering could save chocolate from going ...

Read More...

Dental Stem Cell Potential Explored | Colgate Oral Care

February 16th, 2019 9:41 pm

Scanning through the headlines, tuning in to morning television shows, stem cells are repeatedly the topic of discussion a discussion that increasingly includes primary teeth.

The discovery of stem cells in dental pulp has led to much research and predictions about their potential uses. Although the full possibilities of tooth-derived stem cells are not yet known, some researchers believe that they could one day be valuable for regenerating dental tissues and possibly other tissues as well.

Pamela Robey, Ph.D., chief, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, says that because no one knows for certain what the full possibilities are for the cells isolated from dental pulp, nor can they accurately predict if or when they'll be used in clinical settings, patients and professionals need to make informed decisions.

"What we do know," she said, "is the cells from dental pulp in baby or wisdom teeth have the ability to make dentin and pulp and they might have the ability to make bone but right now that's all we really know for sure."

Because "the data for other things is not hard yet, we can't say how useful for the future they'll be," she said.

Dr. Jeremy Mao, a professor of dental medicine and director of the Tissue Engineering and Regenerative Medicine Laboratory at Columbia University, believes that dental stem cells and related bioengineering technologies will transform dentistry in a magnitude that is far greater than amalgam and dental implants.

"Some of the technologies may happen 10 years down the road but others may happen within 10 years," he predicted.

Presently, there are no human trials taking place with the dental postnatal cells and there are no clinical applications available. There also is no central place for dentists or patients to read about the latest in dental stem cell research. Dr. Robey advised anyone hearing claims of new evidence and dental stem cells to consult the Web site http://www.clinicaltrials.gov.

Read the original post:
Dental Stem Cell Potential Explored | Colgate Oral Care

Read More...

Page 903«..1020..902903904905..910920..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick